Close Menu

Horizon Discovery FFPE, Liquid Biopsy OncoSpan Reference Standards

Horizon Discovery has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays. The company's OncoSpan range now includes formalin-fixed, paraffin-embedded and cell-free DNA formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its genomic DNA format. Its cfDNA format offers more than 380 variants and 152 genes to help standardize liquid biopsy testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.